Russia: Strategy of pharmaceutical industry development up to 2020
Description
The Ministry Decree from 23 October 2009 # 965 the strategy of pharmaceutical industry development up to 2020 was proved. It is aimed at increasing the competitiveness of the domestic pharma industry. The strategy has the following benchmarks:
- Increase of domestic products share in the internal market consumption up to 50 % (in value terms) by 2020.
- Change of assortment of medications sold in Russia, including increase of innovative products number up to 60 % in value terms.
- Increase of pharmaceutical products export by 8 times compared to 2008.
- Provision of medicinal safety of Russia in compliance with the list of strategic medications and vaccines.
- Stimulation of establishing pharmaceutical substances productions on the Russian territory in the volumes necessary for output of 50 % of finished substances (in money terms), including no less 85% by assortment of the list of strategic medications.
The benchmarks are to be achieved through:
1. Stimulation of localization on the Russian territory of high technology production of medicines.
2. Stimulation of establishing production of high technology chemical and biochemical substances in Russia.
3. Stimulation of obligatory transition of the domestic pharmaceutical manufacturers to Good Manufacturing Practice (GMP) standards by 2011.
4. Stimulation of development and production of generic and innovative medicines.
5. Elaboration of new educational programmes and modification of existing ones in order to enhance staff qualification and provide the pharmaceutical industry with new specialists.
6. Provision of medicinal safety of the Russian Federation.
The total finance of the programme for 2009-2020 makes 177 620 mln. roubles (6 billion US dollars).
Any Evidence-Based Deliberation:
| Question | Result |
|---|---|
| Is there anything in the public record to suggest that evidence of the effectiveness of the proposed measure was considered during official deliberations? | |
| Is there any evidence that alternatives to the proposed measure were considered? | |
| Is there anything in the public record that suggests that empirical evidence informed the comparison across the alternatives available to government? | |
| Was such evidence identified? | |
| Is such evidence publicly available? | |
| Did the official decision-maker in question provide an explanation as to why a chosen measure was favoured over alternatives? | |
| Is there any evidence to suggest that potentially affected trading partners were consulted before the measures were taken? | |
| Is there any evidence that safeguards have been put in place to ensure that implementation of the initiative is transparent and non-discriminatory? | |
| Did the government state its intention to review the measure within one year of implementation? |
Date Discovered:
Implemented: Yes
Date of inception: 1 Nov 2009
GTA Evaluation: Amber
Source:
information from the website of the Ministry of Industry and Trade. Available from < http://www.minprom.gov.ru/activity/med/news/45 >
Government Response:
- 340 reads
